nach oben

Erschienen in:

17.10.2020 | Original Research Article

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

verfasst von: Tareq Al Baghdadi, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Patricia Rich, Eugene R. Ahn, Seungjean Chai, Andrew L. Rygiel, Olufunlayo Osayameh, Kaitlyn R. Antonelli, Samiha Islam, Suanna S. Bruinooge, Richard L. Schilsky

Erschienen in: Targeted Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

TAPUR is a pragmatic, phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Sunitinib is an oral multikinase inhibitor of FMS-like tyrosine kinase-3 (FLT-3), among other targets. Results from a cohort of patients with metastatic colorectal cancer (mCRC) with FLT-3 amplification treated with sunitinib are reported.

Objective

This study aimed to investigate whether patients with mCRC with FLT-3 amplification would be responsive to sunitinib, an oral multikinase inhibitor.

Methods

Eligible patients received a standard sunitinib dose of 50 mg orally for 4 weeks followed by 2 weeks off. Simon’s two-stage design was used with the primary study endpoint of objective response (OR) or stable disease (SD) at 16 weeks based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary endpoints were progression-free survival, overall survival, and safety.

Results

Ten patients were enrolled from November 2016 to April 2018. All patients had mCRC with FLT-3 amplification. No ORs were observed. Although two patients had SD at 16 weeks, one died because of disease progression shortly thereafter and the cohort was closed. A single grade 3 adverse event of diarrhea was reported as possibly related to sunitinib.

Conclusions

Monotherapy with sunitinib does not have clinical activity in patients with mCRC with FLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.

Clinical Trial registration

NCT02693535 (26 February 2016).

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA A Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRef

National Cancer Institute. SEER Cancer Stat Facts: Colorectal Cancer. Bethesda, MD. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 21 Feb 2020.

Tomlinson JS, Jarnagin WR, Dematteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. https://doi.org/10.1200/jco.2007.11.0833.CrossRefPubMed

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7. https://doi.org/10.1056/nejm200104053441401.CrossRefPubMed

Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14(4):691–700. https://doi.org/10.1016/j.jtho.2018.12.014.CrossRefPubMed

Langer CJ. The “Lazarus Response” in treatment-naïve, poor performance status patients with non–small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol. 2009;27(9):1350–4. https://doi.org/10.1200/jco.2008.20.4859.CrossRefPubMed

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014;371(20):1877–88. https://doi.org/10.1056/nejmoa1406037.CrossRefPubMed

Bachtiar M, Ooi BNS, Wang J, Jin Y, Tan TW, Chong SS, et al. Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms. Pharmacogenomics J. 2019;19(6):516–27. https://doi.org/10.1038/s41397-019-0096-y.CrossRefPubMedPubMedCentral

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2018;2:1–14. https://doi.org/10.1200/po.18.00122.CrossRef

10.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon Alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. https://doi.org/10.1056/nejmoa065044.CrossRefPubMed

11.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54. https://doi.org/10.1056/nejmoa1611406.CrossRefPubMed

12.

Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38. https://doi.org/10.1016/s0140-6736(06)69446-4.CrossRefPubMed

13.

Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.CrossRef

14.

Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25(30):4793–9. https://doi.org/10.1200/jco.2007.12.8637.CrossRefPubMed

15.

Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, Phase III trial. J Clin Oncol. 2013;31(10):1341–7. https://doi.org/10.1200/jco.2012.45.1930.CrossRefPubMed

16.

Moreira RB, Peixoto RDA, de Sousa Cruz MR. Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification. Case Rep Oncol. 2015;8(1):83–7. https://doi.org/10.1159/000375483.CrossRefPubMedPubMedCentral

17.

Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2019;3:1–8. https://doi.org/10.1200/po.19.00124.CrossRef

18.

Berenstein R. Class III Receptor Tyrosine Kinases in Acute Leukemia—Biological Functions and Modern Laboratory Analysis. Biomarker Insights. 2015;10s3:BMI.S22433. https://doi.org/10.4137/bmi.s22433.

19.

Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol. 2013;97(6):683–94. https://doi.org/10.1007/s12185-013-1334-8.CrossRefPubMed

20.

Rosnet O, Bühring HJ, deLapeyrière O, Beslu N, Lavagna C, Marchetto S, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 1996;95(3–4):218–23. https://doi.org/10.1159/000203881.CrossRefPubMed

21.

Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–42. https://doi.org/10.1182/blood-2002-02-0492.CrossRefPubMed

22.

Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87(3):1089–96.CrossRef

23.

Sutamtewagul G, Vigil CE. Clinical use of FLT3 inhibitors in acute myeloid leukemia. OncoTargets Therapy. 2018;11:7041–52. https://doi.org/10.2147/ott.s171640.CrossRefPubMed

24.

Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650–65. https://doi.org/10.1038/nrc1169.CrossRefPubMed

25.

Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991–1001. https://doi.org/10.1158/1535-7163.mct-16-0876.CrossRefPubMedPubMedCentral

26.

O’Farrell A-M, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, et al. An innovative phase i clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9(15):5465–76.PubMed

27.

Fiedler W, Serve H, DöHner H, Schwittay M, Ottmann OG, O’Farrell A-M, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986–93. https://doi.org/10.1182/blood-2004-05-1846.CrossRefPubMed

28.

Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, et al. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015;169(5):694–700. https://doi.org/10.1111/bjh.13353.CrossRefPubMed

29.

Lim SH, Kim S-Y, Kim K, Jang H, Ahn S, Kim K-M et al. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget. 2017;8(2):3237–45. https://doi.org/10.18632/oncotarget.13700.

30.

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518(7539):422–6. https://doi.org/10.1038/nature13952.CrossRefPubMed

31.

Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–70. https://doi.org/10.1038/nature11252.

32.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: figure 1. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.cd-12-0095.CrossRefPubMed

33.

Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. https://doi.org/10.1038/nature13385.CrossRef

34.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801. https://doi.org/10.1038/nm.3870.CrossRefPubMedPubMedCentral

35.

Braxton DR, Zhang R, Morrissette JD, Loaiza-Bonilla A, Furth EE. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. Int J Cancer. 2016;139(7):1546–56. https://doi.org/10.1002/ijc.30196.CrossRefPubMed

36.

Hasegawa H, Taniguchi H, Kato T, Fujii S, Ebi H, Shiozawa M et al. Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Annals of Oncology. 2019;30(Supplement_5):v240. https://doi.org/10.1093/annonc/mdz246.113.

37.

Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–96. https://doi.org/10.1200/jco.2006.06.3602.CrossRefPubMed

38.

O’Farrell A-M, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–605. https://doi.org/10.1182/blood-2002-07-2307.CrossRefPubMed

39.

Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–32. https://doi.org/10.1038/nbt1358.CrossRefPubMed

40.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. https://doi.org/10.1056/nejmoa1614359.CrossRefPubMedPubMedCentral

41.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40.CrossRef

42.

Ponnurangam S, Standing D, Rangarajan P, Subramaniam D. Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth. 2013;12(5):598–609. https://doi.org/10.1158/1535-7163.mct-12-0907.

43.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. https://doi.org/10.1038/nm.3967.CrossRefPubMedPubMedCentral

44.

Liu Y, Yang EJ, Zhang B, Miao Z, Wu C, Lyu J, et al. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Lett. 2018;436:28–37. https://doi.org/10.1016/j.canlet.2018.08.011.CrossRefPubMed

Titel: Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
verfasst von: Tareq Al Baghdadi
Elizabeth Garrett-Mayer
Susan Halabi
Pam K. Mangat
Patricia Rich
Eugene R. Ahn
Seungjean Chai
Andrew L. Rygiel
Olufunlayo Osayameh
Kaitlyn R. Antonelli
Samiha Islam
Suanna S. Bruinooge
Richard L. Schilsky
Publikationsdatum: 17.10.2020
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 6/2020
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-020-00752-8

Springer Medizin

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study